In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 573-576

  Zhang, Xiaohui ^a,b   Huang, Huaiqiu ^a   Feng, Peiying ^a   Zhang, Jing ^b   Zhong, Yi ^a   Xue, Ruzeng ^b   Xie, Zhi ^c   Li, Meirong ^a   Xi, Liyan ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Center for Skin Diseases   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antifungal drug susceptibility; Dimorphic fungus; Interaction; Itraconazole; Sporothrix schenckii; Terbinafine

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TREATMENT FAILURE; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; SPOROTHRIX SCHENCKII;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; SPOROTHRIX; SPOROTRICHOSIS; STATISTICS, NONPARAMETRIC;

EID: 80052990433     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1400     Document Type: Article

References (18)

1. Lopes-Bezerra LM, Schubach A, Costa RO. Sporothrix schenckii and sporotrichosis. An Acad Bras Cienc 2006; 78: 293-308.
2. Ramos-e-Silva M, Vasconcelos C, Carneiro S, et al. Sporotrichosis. Clin Dermatol 2007; 25: 181-7.
3. Bonifaz A, Fierro L, Saúl A, Ponce RM. Cutaneous sporotrichosis. Intermittent treatment (pulses) with itraconazole. Eur J Dermatol 2008; 18: 61-4.
4. Kikuchi I, Morimoto K, Kawana S, Tanuma H. Usefulness of itraconazole for sporotrichosis in Japan: study of three cases and literature comparison of therapeutic effects before and after release on the market. Eur J Dermatol 2006; 16: 42-7.
5. Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 1255-65.
6. Perea S, Gonzalez G, Fothergill AW, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002; 40: 1831-3.
7. Zhang JM, Xi LY, Zhang H, et al. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora. Eur J Dermatol 2009; 19: 451-5.
8. Ghosh A, Maity PK, Hemashettar BM, et al. Physiological characters of Sporothrix schenckii isolates. Mycoses 2002; 45: 449-54.
9. Trilles L, Torres BF, Lazera MS, et al. In vitro antifungal susceptibility of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother 2005; 49: 3952-4.
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002b.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
12. Kohler LM, Monteiro PC, Hahn RC, et al. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol 2004; 42: 4319-20.
13. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-85.
14. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorain V, ed. Antibiotics in laboratory medicine, 4th ed. Baltimore, Md.: The Williams & Wilkins Co., 1989: 330-96.
15. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
16. Marimon R, Serena C, Gene J, et al. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother 2008; 52: 732-4.
17. Kohler LM, Soares BM, de Assis Santos D, et al. In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms. Can J Microbiol 2006; 52: 843-7.
18. Chaturvedi V, Ramani R, Ghannoum MA, et al. Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of Candida krusei. Antimicrob Agents Chemother 2008; 52: 1500-2.